Introduction
The protozoan parasite Cryptosporidium spp., first described in 1895, 1 causes gastroenteritis in many animal species, including man. 2 In immunocompetent individuals, especially children, the parasite causes self-limiting acute diarrhoea lasting approximately 5-10 days. However, in patients infected with HIV, Cryptosporidium spp. cause severe enteritis and chronic diarrhoea complicated by dehydration and malabsorption. 3 Diarrhoea in these patients may be watery and similar to that observed in cholera; daily fluid loss in the faeces may reach 17 L. 4 These effects lead to significant weight loss and morbidity. Cryptosporidium spp. also cause other diseases in patients with AIDS, such as acalculous cholecystitis, sclerosing cholangitis and respiratory tract disorders. 5 More than 60 drugs have been used for the treatment of cryptosporidiosis in patients with AIDS, but none have consistently been successful. Antibiotics of the macrolide class have been found to be active against Cryptosporidium spp. and have been used with some benefit in the treatment of diarrhoea caused by Cryptosporidium spp. 6, 7 Roxithromycin is a macrolide with better pharmacokinetics than earlier macrolides, such as erythromycin, including excellent intestinal absorption and a long halflife. 8 We undertook the present study to assess the use of roxithromycin in the treatment of AIDS-related cryptosporidiosis.
Materials and methods
HIV-infected patients were enrolled in this study, which took place between 30 July 1993 and 26 March 1996. HIV infection was confirmed by testing for the presence of anti-HIV antibodies using enzyme-linked immunosorbent assay (ELISA; Abbott Laboratories, São Paulo, Brazil). When the test was positive (HIV-1 or -2), the result was confirmed by ELISA (Hoechst Marion Roussel, São Paulo, Brazil) and Western blotting (Cambridge Biotech, Cambridge, MA, USA).
In a pilot study, ten patients with AIDS-related cryptosporidial diarrhoea were treated with roxithromycin 150 mg bd for 4 weeks. There was a complete failure both clinically and parasitologically. Hence, in the present study, patients whose faeces or intestinal biopsy material were positive for Cryptosporidium spp. received an increased dose of roxithromycin (600 mg/day, double the usual dose) for 4 weeks. During this period each patient was seen in the clinic six times: every 4 weeks during treatment, and 2 and 4 weeks after the end of therapy.
At each clinic visit the following information was recorded: weight, body temperature, number of daily evacuations, presence of cramps or vomiting, and concomitant medications. In addition, a full blood analysis was carried out which included platelet determination; serum transaminase, alkaline phosphatase, total and direct bilirubin, gamma glutaryl-transferase and lactic dehydro- © 1998 The British Society for Antimicrobial Chemotherapy JAC genase levels were measured at visits 1, 3, 4, 5 and 6. At visits 1 and 5, CD4 and CD8 lymphocyte counts were determined by indirect immunofluorescence, p24 antigen was determined by ELISA and 2 -macroglobulin levels were measured.
Patients underwent colonoscopy at baseline and 2 weeks after treatment to obtain rectal, sigmoid, transverse and ascending colon biopsy material, which was examined for the presence of acid-fast bacilli, fungi, cytomegalovirusassociated intracellular inclusions and Cryptosporidium spp., using Ziehl-Neelsen, Grocott, haematoxylin-eosin and Giesma staining, respectively. Finally, the faeces were examined for parasites on visits 1, 3, 4, 5 and 6 using a modified Kinyoun technique. For this procedure, the faecal material was fixed in formalin, smear-stained with Carbol Fuchsin for 15 min and decolourized with 10% sulphuric acid for 2 min. The slides were washed in running water, covered with 1% Methylene Blue for 5 min and then examined under a light microscope at 1000 ϫ magnification.
Statistical methods
A repeated measured analysis of variance model (ANOVA) was applied to test alterations in weight (kg), temperature (°C), number of evacuations per day and number of oocysts during the period of treatment with roxithromycin (all visits). In cases of statistical significance, multiple comparisons (Turkey method) were ), the CD4/CD8 ratio, 2 -microglobulin concentration (mg/L) and the presence of p24 antigen, determined at baseline (visit 0) and 2 weeks after treatment (visit 5). A significance level (α) of 5% (P Ͻ 0.05) was used for all tests.
Results
Twenty-six patients (20 males and six females; mean age 36.2 years) began treatment with roxithromycin. Twentytwo patients completed the study. Two patients died during treatment owing to respiratory insufficiency caused by Pneumocystis carinii and two experienced adverse reactions (facial rashes: one an erythematous maculopapular rash and the other acneiform), which may have been caused by roxithromycin but both patients were taking concomitant medications. Both rashes disappeared after treatment was stopped.
Fourteen patients had cryptosporidiosis alone according to the Centers for Disease Control criteria 11 for the diagnosis of opportunistic infections associated with AIDS. The remaining patients had various other diseases associated with, or preceding, cryptosporidiosis (Table I) . Only two patients took roxithromycin alone during the study; concomitant medications are listed in Table I . Patients' mean weight did not change significantly during treatment: 63.2 kg at visit 6 compared with 62.2 kg at visit 1. In contrast, vomiting was significantly reduced (P Ͻ 0.001), as was the number of evacuations (P Ͻ 0.01) ( Table II) .
The number of patients whose faeces and biopsy material were infected with Cryptosporidium spp. on visit 1 and subsequent visits are shown in Table III . Eight patients had positive colonic biopsy results at baseline investigation but were found not to have Cryptosporidium spp. in their faeces as determined microscopically.
In the 22 patients who completed the study, mean CD4 and 2 -microglobulin levels were 253/mm 3 and 4.5 mg/L at the beginning of the study, and 246/mm 3 and 5.3 mg/L at the end of the study, respectively. Twenty-three patients underwent a test for p24 antigen at visit 1 and four tests were positive. Twenty-two of these patients underwent a second test at visit 5 and, on this occasion, five tests were positive.
Transaminase levels increased by almost 2.5 times the reference values in four patients but treatment was not discontinued, all of these patients had normal transaminase levels after treatment, without any specific therapy.
Eight patients complained of cramps during the first 5-8 days of the study and three patients suffered cramps during the fourth week of treatment. All eight patients continued on roxithromycin therapy.
Discussion
AIDS is associated with various opportunistic infections caused by intracellular enteric pathogens. These infections frequently cause chronic disease and sometimes diarrhoea with significant fluid and weight loss, leading to increased morbidity among patients infected with HIV. 12 Cryptosporidium spp. belong to the order Coccidia and are related to Toxoplasma, Isospora, Eimeria and Sarcocystis spp. Like Toxoplasma spp., Cryptosporidium spp. are not species-specific but infect a wide variety of mammals and are transmitted through the ingestion of contaminated water or through faecal contact. The main site of infection is the intestinal epithelium, where spores (oocysts) are formed; ingestion of the oocysts leads to infection. 13 Cryptosporidium spp. are recognized today as one cause of traveller's diarrhoea, 14 but were not studied extensively until the first AIDS cases were reported.
Although symptomatic infection may occur in immunocompetent individuals, the course of the infection is usually self-limiting. 15 The prevalence of Cryptosporidium spp. infection among AIDS patients varies according to geographical region, and is higher in developing countries such as Haiti (50%) and lower in industrialized countries such as the USA (3-4%). 5 Various treatments used for cryptosporidiosis associated with AIDS or with other types of immunodeficiency have been studied, but most of the studies have been small and the results variable and often discouraging, as in the case of spiramycin, 7, 16 zidovudine, 17 bovine transfer factor, 18 paromomycin, 3 somatostatin 19 and human serum immunoglobulin. 20 The present study included 26 patients, 22 of whom completed the study. Roxithromycin caused few sideeffects: two patients presented with skin rashes, but as they were also using other medications it was difficult to attribute these events exclusively to roxithromycin. Four other patients had a slight increase in transaminase levels that did not require discontinuation of treatment. During the 4 week treatment with roxithromycin at a dosage of 300 mg bd, 15 patients (68.2%) were cured and six (27.3%) improved, and treatment failed in one patient. We therefore conclude that roxithromycin is a useful treatment for Cryptosporidium spp. infections in patients with AIDS. 
